0001567619-23-001927.txt : 20230206 0001567619-23-001927.hdr.sgml : 20230206 20230206164703 ACCESSION NUMBER: 0001567619-23-001927 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230202 FILED AS OF DATE: 20230206 DATE AS OF CHANGE: 20230206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ogden Christopher CENTRAL INDEX KEY: 0001914523 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 23591277 MAIL ADDRESS: STREET 1: C/O CYTOMX THERAPEUTICS, INC. STREET 2: 151 OYSTER POINT BLVD., SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2023-02-02 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001914523 Ogden Christopher C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Finance and Accounting Common Stock 2023-02-02 4 A 0 25000 0 A 38288 D Stock Option (Right to Buy) 2.59 2023-02-02 4 A 0 75000 0.00 A 2033-02-01 Common Stock 75000 75000 D Performance Stock Units (PSUs) 2023-02-02 4 A 0 75000 0.00 A Common Stock 75000 75000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date. Includes 32,288 RSUs. Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden 2023-02-06